The Hill covers the fallout from the FDA’s taking tirzepatide off the shortage list — especially how compounders are pushing back — in “Rivals fight for right to sell weight loss drugs.” Of course it quotes APC:
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said in a press briefing that “a lot of patients have been left flat footed” by the FDA ending the shortage.